Features of Cutaneous Microbiome in Children With Atopic Dermatitis and New Pathogenetic Therapy Options
Nikolay N. Murashkin,
Alexander I. Materikin,
Leonid A. Opryatin,
Roman V. Epishev,
Eduard T. Ambarchyan,
Roman A. Ivanov,
Dmitri V. Fedorov https://doi.org/10.15690/pf.v16i5.2060
Abstract
Atopic dermatitis is a chronic inflammatory disease characterized by relapsing course, severe itching, erythema and dry skin due to skin barrier defects and staphylococcus infection. According to current guidelines for the treatment of atopic dermatitis (prepared by dermatological societies) the background therapy is prolonged application of emollients directly on the skin and its use during bathing. Clinical studies have shown that repeated administration of emollients moisturizes the skin, restores its barrier and normal functioning, and reduces the amount of glucocorticosteroids needed for atopic eczema therapy in infants, children and adults. The results of trials and long-term clinical practice have proven that emollients are safe and effective in patients with atopic dermatitis. This article presents the information based on the recent data concerning emollients: their characteristics, mode of action, role in atopic dermatitis treatment, and results of clinical trials conducted in such patients.
Supporting agencies: The article has been funded by Pierre Fabre LLC.
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Moscow
Russian Federation
Moscow
Alexander I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Eduard T. Ambarchyan
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Dmitri V. Fedorov
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Kamińska E. [The role of emollients in atopic dermatitis in children. (In Polish)]. Dev Period Med. 2018;22(4):396–403.
2. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. doi: 10.1038/jid.2013.446.
3. Silverberg NB, Silverberg JI. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. 2015;96(6):359–361.
4. Yamazaki Y, Nakamura Y, Núñez G. Role of the microbiota in skin immunity and atopic dermatitis. Allerg Int. 2017;66(4):539–544. doi: 10.1016/j.alit.2017.08.004.
5. Di Cicco ME, Licari A, Leone M, et al. Impatto del microbioma (polmonare e intestinale) sull’asma [Internet]. Rivista di Immunologia e Allergologia Pediatrica. 2018;2:26–32. Available from: https://www.riaponline.it/article/impatto-del-microbioma-polmonare-e-intestinale-sullasma/.
6. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. 2010;107(26):11971–11975. doi: 10.1073/pnas.1002601107.
7. Gerlich J, Benecke N, Peters-Weist AS, et al. Pregnancy and perinatal conditions and atopic disease prevalence in childhood and adulthood. Allergy. 2018;73(5):1064–1074. doi: 10.1111/all.13372.
8. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol. 2013;69(1):143–155. e3. doi: 10.1016/j.jaad.2013.01.016.
9. Prescott SL, Logan AC. Transforming life: a broad view of the developmental origins of health and disease concept from an ecological justice perspective. Int J Environ Res Public Health. 2016;13(11). pii: E1075. doi: 10.3390/ijerph13111075.
10. Logan AC, Jacka FN, Craig JM, Prescott SL. The Microbiome and mental health: looking back, moving forward with lessons from allergic diseases. Clin Psychopharm Neurosci. 2016;14(2):131–147. doi: 10.9758/cpn.2016.14.2.131.
11. Von Hertzen L, Beutler B, Bienenstock J, et al. Helsinki alert of biodiversity and health. Ann Med. 2015;47(3):218–225. doi: 10.3109/07853890.2015.1010226.
12. Galli E, Maiello N, Ricci G, et al. Il “perché” dello skin care nella dermatite atopica [Internet]. Rivista di Immunologia e Allergologia Pediatrica. 2018;3:22–30. Available from: https://www.riaponline.it/article/il-perche-dello-skin-care-nella-dermatite-atopica.
13. Lunjani N, Satitsuksanoa P, Lukasik Z, et al. Recent developments and highlights in mechanisms of allergic diseases: Microbiome. Allergy. 2018;73(12):2314–2327. doi: 10.1111/all.13634.
14. Nakatsuji T, Gallo RL. The role of the skin microbiome in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(3):263–269. doi: 10.1016/j.anai.2018.12.003.
15. Naik S, Bouladoux N, Linehan JL, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104–108. doi: 10.1038/nature14052.
16. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354. doi: 10.1016/j.jaci.2012.07.012.
17. Laborel-Préneron E, Bianchi P, Boralevi F, et al. Correction: effects of the Staphylococcus aureus and Staphylococcus epidermidis secretomes isolated from the skin microbiota of atopic children on CD4+ T cell activation. PLoS One. 2015;10(11):e0144323. doi: 10.1371/journal.pone.0144323.
18. Volz T, Skabytska Y, Guenova E, et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol. 2014;134(1):96–104. doi: 10.1038/jid.2013.291.
19. Martin H, Laborel-Préneron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4+ T cell activation. Pharm Biol. 2016;54(11):2782–2785. doi: 10.3109/13880209.2016.1173069.
20. Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in Children: Current Clinical Guidelines for Diagnosis and Therapy. Current pediatrics. 2016;15(3):279–294. (In Russ). doi: 10.15690/vsp.v15i3.1566.
21. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.
22. Nakatsuji T, Gallo RL. Dermatological therapy by topical application of non-pathogenic bacteria. J Invest Dermatol. 2014;134(1):11–14. doi: 10.1038/jid.2013.379.
23. Aries MF, Hernandez-Pigeon H, Vaissière C, et al. Antiinflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Clin Cosmet Investig Dermatol. 2016;9:421–434. doi: 10.2147/CCID.S113180.
24. Martin H, Laborel-Préneron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4+ T cell activation. Pharm Biol. 2016;54(11):2782–2785. doi: 10.3109/13880209.2016.1173069.
25. Nguyen T, Castex-Rizzi N, Redoulès D. Activités immunomodulatrice, anti-inflammatoire, antiprurigineuse et tolérogénique induites par I-modulia®, un extrait issu de culture d’ Aquaphilus dolomiae, dans les modèles pharmacologiques de dermatite atopique. Ann Derm Ven. 2017;144 Suppl 1:S42–S49. doi: 10.1016/s0151-9638(17)31042-6.
26. Castex-Rizzi N, Galliano MF, Aries MF, et al. n vitro approaches to pharmacological screening in the field of atopic dermatitis. Br J Dermatol. 2014;170 Suppl 1:12–18. doi: 10.1111/bjd.13106.
27. Bianchi P, Theunis J, Casas C, et al. Effects of a new emollientbased treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol. 2016;33(2):165–171. doi: 10.1111/pde.12786.
28. Fostini AC, Georgescu V, Decoster CJ, Girolomoni G. A cream based on Aquaphilus dolomiae extracts alleviates non-histaminergic pruritus in humans. Eur J Dermatol. 2017;27(3):317–318. doi: 10.1684/ejd.2017.2994.
Review
For citations:
Murashkin N.N., Materikin A.I., Opryatin L.A., Epishev R.V., Ambarchyan E.T., Ivanov R.A., Fedorov D.V. Features of Cutaneous Microbiome in Children With Atopic Dermatitis and New Pathogenetic Therapy Options. Pediatric pharmacology. 2019;16(5):304-309. (In Russ.) https://doi.org/10.15690/pf.v16i5.2060
Views:
871
Email this article 